Danish Commercial Services Stock News

Q1 2026 results snapshot UIE (CPSE:UIE) has kicked off Q1 2026 with revenue of US$162.1 million and a reported loss per share of US$0.87, as net income excluding extra items came in at a loss of US$26.6 million. The company has seen revenue move from US$116.7 million in Q1 2025 to US$162.1 million in Q1 2026. Trailing twelve month EPS across the last reported periods ranged from US$2.37 to US$4.48 before settling at US$2.71 in Q1 2026, which puts the spotlight firmly on how sustainable its...

ISS (CPSE:ISS) has upgraded its 2026 outlook, flagging organic growth above 6% and an operating margin around 5.25%. The company has also expanded its share buyback programme to DKK 3.1 billion. See our latest analysis for ISS. The upgraded outlook, settlement with Deutsche Telekom and larger buyback programme have coincided with firm share price momentum, with a 30 day share price return of 12.36% and a 1 year total shareholder return of 64.03% suggesting improving sentiment over both...

Shareholders appeared unconcerned with Coloplast A/S' ( CPH:COLO B ) lackluster earnings report last week. Our analysis...

Recent share performance and business context Novo Nordisk (CPSE:NOVO B) has drawn attention after recent price moves, with the stock up about 10.4% over the past month but down roughly 7.6% over the past 3 months. For context, the company reports annual revenue of DKK 327,800.0m and net income of DKK 121,957.0m, primarily from its Diabetes and Obesity Care segment, which accounts for DKK 307,350.0m of revenue. See our latest analysis for Novo Nordisk. At a share price of DKK287.5, Novo...

Recent performance snapshot for A.P. Møller Mærsk (CPSE:MAERSK B) A.P. Møller Mærsk (CPSE:MAERSK B) has seen mixed share performance recently, with the stock up 0.5% on the day and 4.8% over the past week, but down 3.3% over the past month. See our latest analysis for A.P. Møller - Mærsk. Looking beyond the recent pullback over the past month, the share price is roughly flat year to date while the 1 year total shareholder return of 18.8% points to stronger longer term momentum. If you are...

As Europe's major indices experience a downturn amid rising geopolitical tensions and inflationary pressures, investors are seeking opportunities in less conventional areas of the market. Penny stocks, often associated with smaller or newer companies, remain an intriguing option despite their somewhat outdated moniker. These stocks can offer growth potential at lower price points when backed by strong financials and solid fundamentals.

As European markets navigate geopolitical tensions and inflationary pressures, the pan-European STOXX Europe 600 Index recently experienced a slight decline, reflecting broader economic challenges. In this environment, dividend stocks can offer investors a potential source of income and stability by providing regular payouts even when market conditions are uncertain.

The subdued market reaction suggests that Solar A/S' ( CPH:SOLAR B ) recent earnings didn't contain any surprises. We...

Earlier this week, Novo Nordisk presented new sub-analyses from its OASIS 4 and STEP UP phase 3 trials at ECO 2026, showing that both oral and high-dose injectable Wegovy produced substantial weight loss and functional improvements in adults with obesity, with safety consistent with the GLP-1 class. The data also indicated that early responders can achieve very large weight reductions, most of the lost weight comes from fat rather than muscle, and oral Wegovy outperformed rival orforglipron...

Event context and recent share performance Ørsted (CPSE:ORSTED) has drawn fresh investor attention following its recent share performance, with the stock up around 27% year to date and about 19% over the past 12 months. See our latest analysis for Ørsted. Recent share price moves have been mixed, with a 10.8% 90 day share price return and a 27.0% year to date share price return, in contrast with a 54.1% decline in three year total shareholder return. This suggests momentum has picked up only...

Bavarian Nordic (CPSE:BAVA) has opened 2026 with Q1 revenue of DKK 1,057.8 million and Basic EPS of DKK 0.20, while the trailing twelve months show revenue of DKK 5.96 billion and Basic EPS of DKK 14.86. This sets a clear snapshot of the current run rate. Over recent quarters, revenue has moved from DKK 2,093.9 million in Q4 2024 to DKK 1,346.6 million in Q1 2025 and DKK 1,057.8 million in Q1 2026. Basic EPS shifted from DKK 10.15 to DKK 2.70 and then DKK 0.20. The latest release therefore...

Last week saw the newest half-year earnings release from Coloplast A/S ( CPH:COLO B ), an important milestone in the...

TORM, ticker CPSE:TRMD A, reported a strong Q1 2026 earnings surge. Geopolitical tensions and the closure of the Strait of Hormuz pushed freight rates to record highs. The company upgraded full year guidance and moved ahead with a fleet renewal plan, adding new vessels. TORM focuses on product tankers that transport refined oil products, so freight disruptions and route changes directly affect its earnings power. With key shipping lanes constrained and rerouted, demand for available,...

Investors were disappointed with the weak earnings posted by Netcompany Group A/S ( CPH:NETC ). While the headline...

Unsurprisingly, Zealand Pharma A/S' ( CPH:ZEAL ) stock price was strong on the back of its healthy earnings report. We...

Coloplast (CPSE:COLO B) Q2 2026 earnings in focus Coloplast (CPSE:COLO B) has kicked off its Q2 2026 reporting with Q1 figures that put hard numbers around the story, with revenue at about DKK7.0 billion, basic EPS of DKK6.21 and net income of DKK1.40 billion. These results are backed by trailing 12 month totals of DKK27.9 billion in revenue, DKK17.70 in EPS and DKK4.0 billion in net income. Over recent quarters the company has seen revenue hover in a tight band between DKK6.93 billion and...

Bavarian Nordic (CPSE:BAVA) is back in focus after securing US$97 million in contract options from the U.S. government for freeze dried smallpox vaccines and lifting its full year 2026 financial guidance. See our latest analysis for Bavarian Nordic. At a share price of DKK194.6, Bavarian Nordic has seen a 1-year total shareholder return of 16.84%, while the 5-year total shareholder return is down 28.27%. This suggests that recent momentum has improved compared with a weaker longer term...

We wouldn't blame Dampskibsselskabet Norden A/S ( CPH:DNORD ) shareholders if they were a little worried about the fact...

A week ago, Zealand Pharma A/S ( CPH:ZEAL ) came out with a strong set of first-quarter numbers that could potentially...

We wouldn't blame Danske Bank A/S ( CPH:DANSKE ) shareholders if they were a little worried about the fact that Carsten...

Genmab A/S ( CPH:GMAB ) shareholders are probably feeling a little disappointed, since its shares fell 3.9% to kr.1,642...

Shareholders might have noticed that Ørsted A/S ( CPH:ORSTED ) filed its quarterly result this time last week. The...

Shareholders might have noticed that GN Store Nord A/S ( CPH:GN ) filed its first-quarter result this time last week...

As you might know, Ambu A/S ( CPH:AMBU B ) last week released its latest quarterly, and things did not turn out so...